Last updated: January 29, 2026
Summary Overview
United States v. Indivior Inc. (Case No. 1:19-cr-00016) is a high-profile federal criminal case centered on allegations of conspiracy, fraud, and misbranding related to the marketing and sale of Suboxone. Indivior Inc., a pharmaceutical manufacturer specializing in opioid addiction treatments, faced federal criminal charges tied to its promotional practices, alleged misrepresentations to healthcare providers, and violations of the Food, Drug, and Cosmetic Act (FDCA).
This case illustrates the intersection of pharmaceutical marketing, regulatory compliance, and criminal liability. It reflects the U.S. Department of Justice's (DOJ) broader efforts to combat opioid-related misconduct and hold corporations accountable for practices that potentially expedited the opioid epidemic.
Case Prompt and Context
- Indivior, a subsidiary of Reckitt Benckiser Group plc, marketed Suboxone (buprenorphine and naloxone), widely prescribed for opioid dependence treatment.
- The allegations include conspiracy to defraud the United States and its programs and violations of the FDCA.
- Indivior allegedly engaged in schemes to mislead government healthcare programs and healthcare providers about the drug’s effectiveness and appropriate use.
Litigation Timeline and Major Developments
| Date |
Event |
Details |
| December 2018 |
Indivior charged |
The DOJ announced an indictment accusing Indivior of engaging in a scheme to boost sales through unlawful marketing tactics. |
| January 2019 |
Case filed |
Formal criminal complaint filed in the District of Columbia (D.D.C.). |
| April 2019 |
Indivior's plea agreement |
Indivior pleads guilty to misbranding Suboxone and agrees to pay $300 million in criminal fines, deferred prosecution agreement (DPA). |
| November 2020 |
Civil settlement |
Reckitt Benckiser pays $1.4 billion in civil and criminal fines related to the case. |
| July 2021 |
Resolutions |
Indivior's DPA with the DOJ concludes, with ongoing monitoring and compliance measures. |
Key Legal Issues and Charges
Criminal Counts
| Count |
Description |
Penalty Range |
Legal Foundation |
| Conspiracy to commit healthcare fraud |
Engaging in schemes to defraud federal healthcare programs |
Up to 10 years imprisonment |
18 U.S.C. § 1349 |
| Misbranding of a drug |
Marketing off-label uses and misrepresentations to increase sales |
Up to 1 year imprisonment per count |
FDCA, 21 U.S.C. § 353 |
Core Allegations
- Misleading Marketing: Indivior promoted Suboxone for unapproved uses, including detoxification and prevention, contrary to FDA approval.
- Off-label Promotion: Evidence indicates that the company incentivized healthcare providers to prescribe Suboxone beyond its labeled indications.
- Suppression of Data: Alleged concealment of data demonstrating risks, including misuse and addiction potential.
- False Statements: Claims made in promotional materials to influence healthcare provider prescribing habits.
Financial Penalties and Settlement Details
| Category |
Amount |
Description |
Sources |
| Criminal fine |
$300 million |
Criminal resolution, paid by Indivior |
[1] |
| Civil settlement |
$1.4 billion |
Civil and criminal fines by Reckitt Benckiser |
[1] |
| Additional penalties |
Ongoing monitoring |
Compliance requirements as per DPA |
[2] |
Note: The penalties reflect the DOJ’s largest opioid-related settlement to date, representing a significant financial consequence designed to deter similar conduct.
Company Response and Compliance Measures
Indivior's Response
- Admitted fault in marketing practices leading to the plea agreement.
- Strengthened internal compliance programs.
- Implemented enhanced training for sales and marketing staff to align with legal and ethical standards.
Post-Settlement Compliance
- Appointment of independent monitors.
- Regular reporting to authorities.
- Development of transparent promotional policies aligning with FDA and DOJ guidelines.
Corporate Impact and Significance
| Aspect |
Impact |
Details |
| Financial |
Heavy fines |
$1.7 billion total liability |
| Reputational |
Damage |
Loss of trust amongst healthcare providers and regulators |
| Operational |
Policy overhaul |
Restructured marketing and compliance procedures |
| Regulatory |
Enhanced scrutiny |
Increased oversight for opioid medications |
Note: The case underscores the importance of compliance programs tailored to pharmaceutical marketing and the legal risks of off-label promotion.
Comparative Analysis with Similar Cases
| Case |
Role of Company |
Penalties |
Core Offenses |
Outcome |
Reference |
| Purdue Pharma (2019) |
Purdue marketed opioids recklessly |
$4.5 billion (criminal, civil) |
Deceptive marketing, misbranding |
Bankruptcy, settlement |
[3] |
| Insys Therapeutics (2019) |
Marketing of Subsys for off-label uses |
$225 million |
Fraud, conspiracy |
Convictions, fines |
[4] |
| Johnson & Johnson (2019) |
Marketing Opioids |
Pending |
Misbranding, misbranding |
Multibillion-dollar settlement |
[5] |
Indivior's case aligns with these precedents, characterized by criminal conspiracy allegations and large fines, signaling a shift towards greater accountability.
Policy and Legal Implications
Regulatory Enforcement Trends
- Increased prosecutions of pharmaceutical companies for off-label marketing.
- Expansion of the FDA’s and DOJ’s authority over promotional material and sales practices.
- Emphasis on transparency and ethical standards in pharmaceutical marketing.
Impact on Industry Practice
- Heightened vigilance among pharma firms regarding compliance.
- Implementation of stricter internal oversight.
- Adoption of comprehensive training on legal boundaries for promotion.
FAQs
Q1: What are the primary legal violations charged in United States v. Indivior Inc.?
A: The core violations involve conspiracy to defraud government healthcare programs and misbranding under the FDCA, linked to unlawful marketing and promotional practices for Suboxone.
Q2: How does the case reflect broader FDA and DOJ policies?
A: It exemplifies increased enforcement against off-label promotion and fraudulent marketing, emphasizing corporate accountability and deterrence regarding opioid-related misconduct.
Q3: What are the key penalties imposed on Indivior and Reckitt Benckiser?
A: Indivior paid a criminal fine of $300 million, while Reckitt Benkiser faced a total civil and criminal settlement of $1.4 billion, with ongoing compliance obligations.
Q4: How has this case influenced pharmaceutical marketing practices?
A: It has prompted the industry to implement more rigorous compliance programs, training, and internal oversight to avoid allegations of off-label promotion and misbranding.
Q5: What are the future legal risks for pharmaceutical companies post-settlement?
A: Companies face heightened risks of investigations, increased regulatory scrutiny, and potential civil or criminal liability if improper marketing practices reoccur.
Key Takeaways
- Legal precedents: The case demonstrates increasing penalties for violations tied to off-label promotion and misbranding, influencing industry standards.
- Regulatory focus: The DOJ and FDA prioritize scrutinizing pharmaceutical marketing practices, especially relating to opioids.
- Financial impact: A combination of criminal fines and civil settlements can reach into billions, emphasizing the financial risks of misconduct.
- Compliance importance: Robust internal controls and adherence to FDA guidelines can mitigate legal risks.
- Industry shifts: The case underlines the necessity for transparency, ethical marketing, and proactive compliance efforts to prevent future litigation.
References
[1] U.S. Department of Justice. (2019). Indivior to Plead Guilty and Pay $300 Million Criminal Fine in Largest-Ever Opioid-Related Prosecution.
[2] Reckitt Benckiser. (2020). Settlement and Compliance Measures.
[3] Purdue Pharma. (2019). Settlement and Bankruptcy Proceedings.
[4] Insys Therapeutics. (2019). Legal Disposition and Corporate Conduct.
[5] Johnson & Johnson. (2019). Pending Litigation and Settlement Details.
This analysis should equip legal professionals, compliance officers, and healthcare industry stakeholders with essential insights into the United States v. Indivior Inc. case, emphasizing compliance, legal risk management, and industry best practices.
